Apstatin, a selective inhibitor of aminopeptidase P, reduces myocardial infarct size by a kinin‐dependent pathway
Why the study?
Does apstatin reduce myocardial infarct size in a rat model of acute ischemia and reperfusion?
Population
Pentobarbital-anaesthetized rats subjected to 30 min left coronary artery occlusion followed by 3 h…
Comparison
Apstatin, ramiprilat, or their combination… vs Saline
Design
Preclinical
Follow-up
3 hours of reperfusion
Authors
Discussion
Loading...
Member takes
Implication
May support bradykinin-mediated cardioprotection in rodent ischemia-reperfusion; leaves open translation to human acute MI.
Structured PICO
Does apstatin reduce myocardial infarct size in a rat model of acute ischemia and reperfusion?
P
Population
Pentobarbital-anaesthetized rats subjected to 30 min left coronary artery occlusion followed by 3 h reperfusion
I
Intervention
Apstatin (aminopeptidase P inhibitor), ramiprilat (ACE inhibitor), or their combination administered 5 min before ischaemia (with or without HOE140 pretreatment)
C
Comparator
Saline
O
Outcome
Myocardial infarct size (IS) determined by tetrazolium staining and expressed as percentage of the area at risk (AAR)surrogate
Apstatin reduces myocardial infarct size in a rat model of ischemia-reperfusion to a similar extent as ramiprilat, mediated by a bradykinin-dependent pathway.
Cite This Study
Wolfrum et al. (2001) studied this question.